Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
Olaparib is recommended, within its marketing authorisation, as an option for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who ...
AstraZeneca, which received approval for Olaparib in 2018 ... been directed to withdraw the said indication and revise the package insert" the DCGI said in a letter, which was reviewed by Mint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback